<DOC>
	<DOCNO>NCT01872182</DOCNO>
	<brief_summary>The main objective study evaluate efficacy safety ALS-L1023 tablet patient abdominal obesity metabolic syndrome .</brief_summary>
	<brief_title>Efficacy Safety Study ALS-L1023 Patients With Abdominal Obesity Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Obesity , Abdominal</mesh_term>
	<criteria>Aged 20 64 year ( Both gender ) 2 among component metabolic syndrome Triglyceride &gt; = 150mg/dL HDLD : Women &lt; 50mg/dL Men &lt; 40mg/dL Hypertension : Systolic blood pressure &gt; = 130mmHg Diastolic blood pressure &gt; = 85mmHg Hyperglycemia : fasting plasma glucose &gt; = 100 mg/dL Informed consent award Alcohol drug abuse Any investigational medication precede 3 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>